Terms & Conditions

Important Information

You must read and accept this important notice before you attempt to access the electronic version of the Prospectus through our website. The information on this page is not part of the Prospectus.

The Prospectus is an important document that should be read it its entirety. If you do not understand it, please consult your professional adviser without delay.

Lodgement of Prospectus with ASIC

The Prospectus relates to a proposed initial public offering of 58.6 million Shares at an Offer Price of A$0.29 by The Hydration Pharmaceuticals Company Limited (ACN 620 385 677) (the Company or Hydralyte North America) to raise A$17.0 million (Offer). The Prospectus is dated 3 November 2021, which was the date of lodgement with ASIC.

Electronic Prospectus

Any person accessing the electronic version of this Prospectus must be an Australian resident and must only access the Prospectus from within Australia. Persons who access the electronic version of this Prospectus should ensure that they download and read the entire Prospectus.

The Corporations Act prohibits any person passing onto another person an Application Form unless it is attached to a hard copy of this Prospectus or it accompanies the complete and unaltered version of this Prospectus. Any person may obtain a hard copy of this Prospectus free of charge by contacting the Company. If you have received this Prospectus as an electronic Prospectus, please ensure that you have received the entire Prospectus accompanied by an Application Form. If you have not, please contact the Company so either a hard copy or a further electronic copy of the Prospectus or both can be sent to you for free.

No advice

Nothing contained on this website or in the Prospectus constitutes investment, legal, business, tax or other advice. In particular, the information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. In making an investment decision, you must rely on your own examination of the Company, the Shares and the terms of the Offer, including the merits and risks involved. You should consult your professional adviser for legal, business or tax advice.

Warning

It is the responsibility of any Applicant outside Australia to ensure compliance with all laws of any country relevant to their Applications, and any such Applicant should consult their professional advisers as to whether any government or other consents are required, or whether any formalities need to be observed to enable them to apply for and be allotted any securities.

For legal reasons, the electronic version of the Prospectus accessible through this website is available to persons accessing this website from within Australia only. If you are accessing this website from anywhere outside Australia, please do not download the electronic version of the Prospectus.

The distribution of this Prospectus (including an electronic copy) in jurisdictions outside of Australia may be restricted by law and therefore persons outside Australia who obtain the Prospectus should seek advice on, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The Prospectus does not constitute an offer of securities in any jurisdiction where, or to any person to whom, it would not be lawful to issue the Prospectus or make the offer.

The Prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to any US person (as defined in Regulations under the US Securities Act of 1933, as amended (‘US Securities Act’)), and is not available to persons in the United States or to US persons. The securities in the offering have not been and will not be registered under the US Securities Act or the securities laws of any state of the United States and may not be offered or sold in the United States or to US persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable state securities laws.

By accessing the Prospectus and clicking the “Agree and Download” link below, you acknowledge and agree to the above.

Agree and Download

Further Information

If you have any questions, you should seek advice from your stockbroker, accountant or other professional adviser or call the Hydralyte North America Offer Information Line on 1300 288 664 (within Australia) or +61 (2) 9698 5414 (outside Australia) from 9:00 am to 5:00 pm (Melbourne time), Monday to Friday (excluding public holidays).